The IP6K1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of inositol hexakisphosphate kinase 1 (IP6K1). This product provides a mixed population of HeLa cells harboring heterogeneous CRISPR/Cas9-mediated disruptions at the IP6K1 locus, enabling functional analysis of IP6K1-dependent processes without prior single-cell cloning. The polyclonal format preserves population-level biological variability while effectively abolishing IP6K1 expression, offering a robust model for investigating the roles of inositol pyrophosphate signaling in cancer biology and metabolic regulation.
The host cell line is HeLa, an immortalized human cervical carcinoma cell line derived from a cervical adenocarcinoma. HeLa cells are widely used in biomedical research due to their robust growth, genetic tractability, and well-characterized signaling networks. Notably, these cells are HPV-18 positive and express the E6 and E7 oncoproteins, which inactivate the tumor suppressors p53 and retinoblastoma protein (Rb), respectively. This genetic background makes HeLa cells particularly suitable for studying oncogenic signaling, DNA damage responses, and metabolic rewiring in a p53-deficient context, which is relevant for many cancer types.
IP6K1 catalyzes the phosphorylation of inositol hexakisphosphate (IP6) to generate the higher inositol pyrophosphate 5-diphosphoinositol pentakisphosphate (IP7). IP7 functions as a second messenger by directly binding the pleckstrin homology (PH) domain of AKT, thereby inhibiting its membrane recruitment and subsequent activation. This suppresses downstream anabolic signaling through the PI3K?CAKT?CGSK3?? axis. IP6K1 activity is regulated by upstream signals including insulin, nutrients, and protein kinase A (PKA), and it interacts with IP6 and PPIP5 kinases. Downstream, IP6K1-generated IP7 modulates key targets such as AKT, GSK3??, and ATM, thereby integrating metabolic, growth, and DNA repair signals. Consequently, IP6K1 acts as a negative regulator of insulin signaling and a modulator of genome stability.
In the HeLa background, IP6K1 disruption is expected to reduce IP7 levels, relieving inhibition on AKT and potentially enhancing PI3K/AKT pathway activity. Given HeLa cells’ reliance on AKT signaling for survival and proliferation, this knockout model provides a powerful tool for dissecting the contributions of inositol pyrophosphates to cancer cell metabolism and oncogenic signaling. Additionally, because HeLa cells harbor inactivated p53, this system allows investigation of IP6K1’s role in p53-independent DNA damage responses, particularly through the ATM pathway. The model may also reveal how HPV-driven cancers exploit inositol phosphate metabolism to sustain growth and evade repair mechanisms.
Key applications include studies of insulin resistance mechanisms, inositol pyrophosphate signaling dynamics, and DNA damage response pathways. Researchers can employ assays such as western blotting for phospho-AKT (S473) and total AKT to assess pathway activation, HPLC-based inositol phosphate profiling to quantify IP6/IP7 levels, and ??H2AX immunostaining to evaluate DNA damage. Cell viability and proliferation assays under metabolic stress further characterize the functional impact of IP6K1 loss. This product is ideal for drug discovery screening and mechanistic studies in cancer metabolism and signaling. For additional technical details or customization, please contact Ascent Research.
